- Integrated DNA Technologies (IDT) has launched the Alt-R™ HDR Enhancer Protein to increase homology-directed repair (HDR) efficiency in difficult-to-edit cells.
- The product is manufactured by Aldevron, a CDMO, to meet rigorous quality standards for therapeutic research use.
Integrated DNA Technologies (IDT) has announced the launch of its Alt-R™ HDR Enhancer Protein, a new solution designed to improve genome editing outcomes in challenging cell types. The molecule enables up to a two-fold increase in HDR efficiency in cells such as induced pluripotent stem cells (iPSCs) and haematopoietic stem and progenitor cells (HSPCs).
The protein-based enhancer, manufactured by Aldevron, a global CDMO and fellow Danaher operating company, is designed to maintain cell viability and genomic integrity without increasing off-target edits or translocations. It broadens IDT’s existing portfolio of reagents aimed at supporting cell and gene therapy developers.
“It’s exciting to see from early access users that this pathway specific, protein-based enhancer shifts the DNA repair pathway balance toward HDR, promoting more precise genome modification without compromising cell viability or genomic integrity, demonstrating its scalability in therapeutic development applications.”
Sandy Ottensmann, Vice President and General Manager, Gene Writing & Editing at IDT
The Alt-R HDR Enhancer Protein has demonstrated efficacy across multiple loci and cell types in early studies. Available initially in research-use-only format at 500 μg and 5 mg, a CGMP-grade version will follow to support translational and therapeutic applications.
IDT stated that the new reagent integrates seamlessly into existing gene editing workflows, offering compatibility with different Cas systems and delivery methods. Together with its CRISPR portfolio, the launch reinforces the company’s role in advancing next-generation genome engineering for research and clinical applications.
